Skip to content
About
Leadership
Executive Team
Board of Directors
Scientific Advisory Board
Facilities
Therapeutic Areas
Central Nervous System
Fibromyalgia
Posttraumatic Stress Disorder
Long COVID
Cocaine Intoxication
Migraine
Depression
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Long COVID
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-601 CR
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-102 SL
TNX-1840/TNX-1850
TNX-3500
TNX-801
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit
www.resilientstudy.com
or
www.clinicaltrials.gov
(NCT05273749).
June 2022
TNX-1500, an Fc-modified Anti-CD154 Antibody,
Prolongs Nonhuman Primate Cardiac Allograft Survival
June 2022
Long Term Rejection Free Renal Allograft Survival with Fc Modified Anti CD154 Antibody Monotherapy in Nonhuman Primates
June 2022
Novel Targetable Pathways in Costimulation Pathway Blockade
June 2022
The Virus-host Interface: A Treasure Trove of Novel Antiviral Targets
June 2022
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox
November 2021
TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder
November 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
July 2020
Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)
June 2021
Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
June 2021
Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD
Posts navigation
Older posts
